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Abstract 12 
In this work we report the synthesis of a series of derivatives of N-benzyl-2-phenylethanamine 13 
which is the framework of norbelladine, the natural common precursor of the Amaryllidaceae 14 
alkaloids. These compounds were assessed in the inhibition of both AChE and BChE which 15 
are the enzymes responsible for the breakdown of acetylcholine and hence they constitute 16 
targets in the palliative treatment of Alzheimer disease. In particular, brominated derivatives 17 
exhibited the lowest IC50 values against AChE. Interestingly, the presence of iodine in one of 18 
the aromatic rings highly increased the inhibition of BChE compared to its analogues, with an 19 
IC50 value similar to that of galantamine, which was the reference compound currently used in 20 
the treatment of AD. A possible mechanism of action for these compounds was determined by 21 
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AD: Alzheimer Disease 30 
ACh: acetylcholine 31 
AChE: Acetylcholinesterase 32 
BChE: Butyrylcholinesterase 33 
IC50: half maximal inhibitory concentration 34 
Gal: Galantamine 35 
MD: Molecular Dynamics36 


































































































































1. Introduction 37 
Alzheimer’s disease (AD) is the most common type of dementia among older adults which is 38 
characterized by chronic neurodegenerative pathology that causes a significant and 39 
progressive functional disability, loss of cognition and altered behavior. Several factors have 40 
been described to play a role in the pathogenesis of AD including a deficit of acetylcholine 41 
(ACh), tau-protein aggregation and extracellular deposits of amyloid plaques. Consequently, 42 
multiple pharmacological targets can be tackled as a palliative treatment for this disease 1,2. 43 
Cholinesterase inhibitors have been developed as therapeutic agents for AD based on the 44 
cholinergic dysfunction hypothesis which states that low levels of ACh lead to cognitive 45 
impairment and dementia 3. The human brain contains two different cholinesterases: 46 
acetylcholinesterase (AChE; EC 3.1.1.7) and butyrylcholinesterase (BChE; EC 3.1.1.8) which 47 
are the enzymes responsible for hydrolyzing the neurotransmitter ACh into choline and 48 
acetate. Currently, only three AChE inhibitors have been approved by the FDA and used for 49 
the palliative treatment of mild to moderate symptoms of AD: galantamine, donepezil and 50 
rivastigmine. AChE has gained great relevance as a target for novel drug discovery because 51 
of its dual functionality: ACh hydrolysis and amyloid beta peptide aggregation  4. On the other 52 
hand, BChE has a role in the hydrolysis of ACh but also non-enzymatic functions, such as 53 
being involved in anti-inflammatory pathways and delaying the rate of neurotoxic amyloid-β 54 
fibril formation 5 which foster the study of this enzyme as an important target in AD 55 
pharmacotherapy.  56 
Several studies have been performed in order to discover novel anticholinesterases either as 57 
naturally-occurring compounds or synthetic inhibitors. Plant species and their potentially active 58 
compounds such as terpenes, coumarins, polyphenols and alkaloids have been screened for 59 
anti-AChE activity being the latter the most potent compounds assessed 6. Recently, some 60 
molecules have been designed and synthesized based on different scaffolds such as 61 
chalcone-derivatives 7–9, 1,2,3-triazole-chromenone carboxamides 10, dibenzo-γ-pyrones 11, 62 
benzofurans 12, spirooxindoles 13, tacrine-ferulic acid and quinoline-ferulic acid hybrids as 63 
multi-target-directed ligands 14,15, among many others 2. Most of them have shown moderate to 64 
significant cholinesterase inhibitory activity. Also, the modification of natural compounds by 65 
xenobiotic biotransformation has been a tool to increase their biological activity 16. 66 
Norbelladine is an alkaloid-like amine (protoalkaloid) resulting from the condensation of 3,4-67 
dihydroxybenzaldehyde -protocatechuic aldehyde- (derived from phenylalanine) and tyramine 68 


































































































































(derived from tyrosine). This is the common precursor in the biosynthesis of all Amaryllidaceae 69 
alkaloids which is further regioselectively methylated to give 4’-O-methylnorbelladine that can 70 
undergo three different types of oxidative phenol coupling reactions (para-para’, ortho-para’, 71 
ortho’-para couplings) to give alkaloids such as haemanthamine, lycorine and galantamine. 72 
The latter is primarily isolated from daffodil (Narcissus spp.), snowdrop (Galanthus spp.), and 73 
summer snowflake (Leucojum aestivum) and has been used in the palliative treatment of 74 
Alzheimer’s disease in the early stages 17,18. The potential health effects of the Amaryllidaceae 75 
alkaloids have been widely investigated 19 although there are a limited number of studies of 76 
the bioactivities of their precursors. One recent example is the antioxidant and anti-77 
inflammatory effects of norbelladine via scavenging radicals and inhibiting both COX-1 and 2 78 
enzymes 20.  79 
Halogens in ligand–target complexes play an important role due to steric aspects that 80 
influence their conformation, allow intermolecular interactions that favorably contribute to the 81 
stability and also increase membrane permeability 21. Although less abundant than fluorine-82 
containing drugs which are estimated 20 % of all pharmaceuticals, there are interesting 83 
examples of commercially available organobromine drugs, such as the mucolytic drug 84 
bromhexine, the vasodilator nicergoline, the sedative and hypnotic brotizolam and non-85 
steroidal anti-inflammatory for ophthalmic use bromfenac 22. On the other hand, iodine is 86 
highly used in nuclear medicinal diagnostic techniques and there are a few examples of 87 
iodine-containing organic compounds such as iobenguane, a blocking agent for adrenergic 88 
neurons, I131 iodocholesterol with diagnostic imaging activity, 4'-iodo-4'-deoxydoxorubicin with 89 
antiamyloid activity and 4-iodopropofol, an alkylphenol derivative with anticonvulsant activity 23. 90 
In the present study, inspired by the common precursor of Amaryllidaceae alkaloids, we 91 
synthesized a series of substituted N-benzyl-2-phenylethanamine based on the norbelladine 92 
structure as a scaffold. Most of the compounds bear a halogen atom on one of the aromatic 93 
rings. These compounds were assessed as cholinesterase inhibitors and a plausible 94 
mechanism of action was explained by molecular modeling studies using combined 95 
techniques such as docking calculations and molecular dynamics simulations. As a result, the 96 
possible stereo-electronic requirements for these ligands were also discussed regarding to 97 
their different affinities. 98 
2. Results and discussion 99 
2.1. Synthesis of norbelladine analogues 100 


































































































































N-benzyl-2-phenylethanamine (norbelladine framework) was used as a key unit to design new 101 
analogues with different substitution patterns mainly at the A-ring. 4’-O-methylnorbelladine and 102 
several non-natural analogues were synthesized by condensation of substituted aromatic 103 
aldehydes (1-9) and tyramine (10) or phenylethylamine (11) to form the Schiff base and further 104 
reduced with sodium borohydride. The reductive amination to obtain 4’-O-methylnorbelladine 105 
(12) has been already described in literature with different yields 24–27. Several experiments 106 
were conducted to improve the isolated yields, especially using some Lewis acid catalysts, 107 
bases and dehydrating agent in the reaction mixture as well as different temperatures (data 108 
not shown). The best results were obtained at room temperature in methanol using anhydride 109 
sodium sulfate as a desiccant and triethylamine (TEA) or KOH as a base to increase the 110 
nucleophile strength of the primary amine giving the desired products. Most of the halogenated 111 
norbelladine analogues precipitated during the work-up procedure in the alkaline aqueous 112 
medium at their corresponding isoelectric point and thus were purified by filtration and simple 113 
recrystallization. However, to recover 12 after work-up, it was necessary to perform a partition 114 
with ethyl acetate. As a result, a library of ten synthetic analogues of norbelladine was 115 
obtained in yields ranging from 51-92 % with purity higher than 96 % determined by GC-FID or 116 
GC-MS. The halogenated compounds were synthesized from the corresponding aldehydes as 117 







Fig. 1. Reductive amination for the synthesis of norbelladine analogues 125 
12 R1: H R2: OH     R3: OCH3    R
4: H R5: OH 
13 R1: Cl R2: OH     R3: OCH3    R
4: H R5: OH 
14 R1: Br R2: OH     R3: OCH3    R
4: H R5: OH 
15 R1: I R2: OH     R3: OCH3    R
4: H R5: OH 
16 R1: H R2: OH     R3: OCH3    R
4: Br R5: OH 
17 R1: H R2: H        R3: F R4: H R5: OH 
18 R1: H R2: H        R3: Cl R4: H R5: OH 
19 R1: H R2: H        R3: Br R4: H R5: OH 
20 R1: H R2: H        R3: OH R4: H R5: OH 
21 R1: Br R2: OH     R3: OCH3    R
4: H R5: H 


































































































































2.2. Cholinesterase inhibitory activity 126 
The synthesized compounds were tested for cholinesterase inhibition of both Electrophorus 127 
electricus AChE and equine butyrylcholinesterase BChE according to Ellman’s method 28 with 128 
some modifications 29, and the results were expressed as IC50 values. In order to make the 129 
compounds more water-soluble for the bioassays and avoid the use of co-solvents, the 130 
hydrochloride salts of 12-14 were prepared. No significant differences in the IC50 values for the 131 
inhibition of AChE or BChE were observed for the compounds with free amines compared to 132 
the amine salt (see Table S1). 133 
Compounds 13, 14, 16 and 21 showed the lowest IC50 values for AChE inhibition. The 134 
introduction of halogenated substituents at the A-ring improved the cholinesterase inhibition 135 
compared to the natural compound 4’-O-methylnorbelladine (12) with the exception of iodine. 136 
Other authors have also discussed how the presence of halogens on thiophene chalcones and 137 
pyrazoline derivatives exerted an increase in the cholinesterase inhibition 7,8. Brominated 138 
compounds on 2’ position 14 and 21 were the most effective inhibitors against AChE exhibiting 139 
IC50 values of 16.79 ± 0.51 and 17.14 ± 3.17 µM, respectively, differing by one order of 140 
magnitude higher than the positive control galantamine (IC50 of Gal: 1.2 ± 0.1 µM). These 141 
studies suggest that the brominated derivatives of 12 show higher cholinesterase inhibition 142 
than their analogues, being good candidates to deepen for this bioactivity. On the other hand, 143 
monosubstituted derivatives (17-20) at the A-ring displayed no inhibition activity towards 144 
AChE. However, with the exception of the fluorinated compound 17, they all showed to some 145 
extent some inhibition of BChE, being the brominated analogue the best inhibitor for this 146 
enzyme with an IC50 value of 23.90 ± 6.26.  147 
Interestingly, when the OH group at the B-ring was not present (compound 21) the product 148 
exerted a high inhibition of both cholinesterases with IC50 of 17.14 ± 3.17 for AChE and 13.35 149 
± 3.01 for BChE. This latter value was comparable to Gal (IC50 of 15.88 ± 1.6 µM). Also, 150 
compound 15 showed a high selectivity for BChE inhibition showing an IC50 value of 13.34 ± 151 
2.79 µM.  152 
 153 
154 


































































































































Table 1 155 












 IC50 [µM] Selectivity 
to BChE AChE  BChE  
12 H OH OCH3 H OH 69.26±0.52 65.48±4.84 1.05 
13 Cl OH OCH3 H OH 36.18±4.99 62.25±4.64 0.58 
14 Br OH OCH3 H OH 16.79±0.51 49.91±3.01 0.34 
15 I OH OCH3 H OH 173.66±14.78 13.34±2.79 13.01 
16 H OH OCH3 Br OH 34.79±4.52 30.32±1.81 1.15 
17 H H F H OH >200 >200 n.d. 
18 H H Cl H OH >200 159.27±28.44 n.d. 
19 H H Br H OH >200 23.90±6.26 n.d. 
20 H H OH H OH >200 52.98±8.58 n.d. 
21 Br OH OCH3 H H 17.14±3.17 13.35±3.01 1.28 
Gal*  1.21±0.06 15.88±1.65 0.08 
AChE and BChE inhibition is expressed as the mean ± SD (n = 3 experiments). Selectivity to BChE: 158 
IC50 for AChE/IC50 for BChE. *Galantamine (Gal) was used as positive control. n.d.: not determined. 159 
 160 
2.3. Molecular modeling studies 161 
In order to have a better understanding of the experimental results obtained, we carried out a 162 
molecular modeling study for compounds 12-21. It should be noted that calculations were 163 
carried out considering that the amino group is protonated at physiological pH. Results 164 
previously reported by our group regarding to a well-known AChE inhibitor, galantamine, was 165 
also included here for discussion 29,30. This study was performed in three stages. First, we 166 
conducted docking calculations which led us to find the probable modes of interaction between 167 
ligands and the active site of both enzymes. Next, we performed molecular dynamics (MD) 168 
simulations with the aim of analyzing compound behavior over time. In the last stage, using 169 
the trajectories obtained from MD simulations, we calculated free energy of different 170 
complexes and carried out a per-residue analysis in order to identify the AChE and BChE 171 
active site amino acids involved in the intermolecular interactions of the different complexes. 172 
Although biological tests were performed with EeAChE, the crystalline structure of TcAChE 173 


































































































































was used in molecular modeling studies. This is possible since both enzymes are considered 174 
structurally homologous 31. The ligand binding pockets in TcAChE, EeAChE and even AChE in 175 
vertebrates, have almost the same geometry, therefore, they are expected to bind inhibitors in 176 
a very similar manner 31–33. 177 
Considering the experimental results, it should be noticed that most compounds reported here 178 
showed greater inhibitory activity against BChE than that observed against AChE. This might 179 
be due to the difference in the active sites of both enzymes. BChE active site presents a larger 180 
accessible area than the AChE active site since it has a lower number of aromatic residues in 181 
its binding pocket 34. Both enzymes have over 60% of sequence identity and show a similar 182 
response to a number of classical inhibitors since the amino acid sequence at the active site of 183 
both AChE and BChE is well conserved 35. Additionally, the existence of a catalytic triad (Ser, 184 
His and Glu) in the active site is considered important for the catalytic activity of both enzymes 185 
36,37. However, six residues, i.e. Tyr70, Tyr121, Trp279, Phe288, Phe290 and Phe330, with 186 
bulky aromatic side chains present in the AChE active site are substituted by non-aromatic 187 
residues of Asn68, Gln119, Ala277, Val286, Val288 and Ala328 in BChE. This may generate 188 
the appropriate conditions for these compounds to better accommodate in the active site of 189 
BChE. 190 
4’-O-methylnorbelladine (12) and its halogenated derivatives at C2 (13-15) showed AChE 191 
inhibitory activity, being compound 14 one the most active of all analogues studied here. 192 
Figure 2A shows the main interactions stabilizing 14-AChE complex. These interactions 193 
involve the following enzyme residues: Gln69, Trp84, Gly118, Ser122, Gly123, Ser124, 194 
Phe330 and Tyr334. Our simulations suggest that OH at C3 (A-ring) establishes an H-bond 195 
with the side chain of Gln69 and that OMe at C4 interacts with Ser124 backbone (Figure S1). 196 
The interactions with residues Trp84, Gly118, Ser122 and Phe330 are the same to those 197 
previously reported for galantamine 30 (Figure 2B), suggesting that these compounds are 198 
located in the same AChE region. It should be noted that activity increases when H at C2 of 199 
compound 12 is substituted by chlorine and bromine, resulting in compounds 13 and 14, 200 
respectively. It is important to highlight that 14 is about 4 times more active than 12. The 201 
presence of a halogen atom in norbelladine analogues allows intermolecular interactions that 202 
favorably contribute to the stability of the complexes. However, it seems that halogen atoms 203 
also play an important role from the steric point of view; compound 15 with an iodine atom 204 
showed the lowest activity of this series. These results could be related to the AChE active site 205 
size, since compounds with bulky substituents cannot accommodate properly to establish 206 


































































































































favorable interactions compared to the other compounds of the same series (compare 207 
inhibitory effects of compounds 13-15). Figure 3 shows the histogram obtained for compound 208 
15. In this case significant interactions were observed for Asp72, Tyr121 and Trp279, all of 209 
them belonging to the peripheral anionic site or bottleneck region 37. These results suggest 210 
that compound 15 is located out of the AChE active site and establishes a different interaction 211 
pattern in comparison with compounds 13 and 14, which could explain its poor activity.  212 



































































































































Fig. 2. Histograms of interaction energies partitioned with respect to AChE amino acid sequence when 214 
complexed with compound 14 (A), Gal (B) and compound 17 (C). The X-axis denotes the residue 215 
number of AChE and the Y-axis denotes the interaction energy between the compounds and a specific 216 
residue. Negative values and positive values are favorable or unfavorable to binding, respectively. 217 



































































































































Fig. 3. Histograms of interaction energies partitioned with respect to AChE amino acid sequence when 219 
complexed with compound 15. The X-axis denotes the residue number of AChE and the Y-axis denotes 220 
the interaction energy between the compounds and a specific residue. Negative values and positive 221 
values are favorable or unfavorable to binding, respectively. 222 
 223 
Regarding 21, one of the most active compounds with an IC50 value of 17.14 ± 3.17 µM, it is 224 
structurally very similar to 14, being their only difference the lack of OH at B-ring. This 225 
suggests that the presence of this substituent in this position is not an important structural 226 
requirement for inhibition activity. 227 
On the other hand, monosubstituted derivatives at the A-ring (17-20) showed IC50 values ≥ 228 
200 µM for AChE, and therefore, they were considered as inactive. Figure 2C shows the 229 
histogram corresponding to 17, as an example of these inactive compounds. It should be 230 
noted that due to the different pattern of substitutions, the important interactions with Gln69 231 
and Ser122 discussed above are missing for this compound.  232 
Regarding BChE, Figure 4A shows the histogram obtained for compound 15. The main 233 
interactions stabilizing the complex are Trp110, Glu225, Phe357, and His466 among others. 234 
Similar results were obtained for the rest of the active compounds. Comparing these results 235 
with those observed for BChE-Gal complex 29 (Figure 4B), it is reasonable to assume that 236 
derivatives 12-21 interact with the same region of the enzyme. In all complexes, the 237 
protonated amino group of ligands is oriented towards the carboxyl group of Glu225, 238 
establishing a salt bridge in most cases (Figure S2). 239 



































































































































Fig. 4. Histograms of interaction energies partitioned with respect to BChE amino acid sequence when 241 
complexed with compound 15 (A), Gal (B) and compound 17 (C). The X-axis denotes the residue 242 
number of BChE and the Y-axis denotes the interaction energy between the compounds and a specific 243 
residue. Negative values and positive values are favorable or unfavorable to binding, respectively. 244 
 245 


































































































































On the other hand, the inhibitory effect of compounds 13 to 15 increases with the atomic 246 
radius of the halogen in position R1. This might be due to the possibility that the iodine 247 
substituent in 15 establishes a higher number of interactions with neighboring amino acids 248 
than the rest of halogen derivatives tested. Compound 15 with IC50 value lower than 249 
galantamine, establishes strong interactions with Trp110, Glu225 and His466 (Figure 4A). In 250 
this line, the presence of the OH substituent at the B-ring seems to be important for this 251 
compound to show inhibitory activity since an H-bond can be formed with the backbone of 252 
Trp110 (Figure S2). It is important to notice that compound 15 is the most active against BChE 253 
in this series. However, this compound does not display significant inhibitory activity against 254 
AChE. As discussed above, the amino acid sequence in BChE active site allows to 255 
accommodate bulkier ligands if compared to AChE. Figure 5 represents the spatial view of 256 
both cholinesterases active sites when complexed with compound 15. As can be 257 
seen, 15 adopts a different spatial arrangement in each complex. In 15-AChE complex (Figure 258 
5A), the ligand remains close to the surface of the active site interacting with amino acid 259 
residues from the peripheral anionic site and the bottleneck region. In contrast, in the 15-BChE 260 
complex (Figure 5B), the ligand is located deeper in the gorge and can interact with the 261 
catalytic triad and the acyl-binding pocket of the cholinesterase. 262 
A B
 263 
Fig. 5. Active sites of Torpedo californica acetylcholinesterase (AChE) (A) and Equus caballus 264 
butyrylcholinesterase (B) when complexed with compound 15 which is represented in ball and stick and 265 
colored in blue. The gorge of each enzyme is depicted by its molecular surface in semi-transparent 266 
gray. The main amino acid residues from both active sites are also shown. The catalytic triad and 267 
oxyanionic subsite residues are in magenta. The acyl-binding pocket amino acids are in orange. The 268 
anionic subsite is colored in yellow. The peripheral anionic site is represented in cyan. The residues 269 
from the bottle neck region are in green. 270 


































































































































The inactive compound 17 (IC50 > 200 µM) showed a different interaction pattern and 271 
interaction energy values in comparison with 15-BChE and 21-BChE. In Figure 4C, it can be 272 
seen that in 17-BChE interactions with Trp110 and His466 are significantly decreased. The 273 
main interactions stabilizing the 17-BChE complex are those with Met109, Val155, Tyr468 and 274 
Glu471. 275 
An unexpected result was the remarkable inhibitory activity of compound 21 (IC50 = 13.35 ± 276 
3.01 µM) despite the lack of the OH substituent in B-ring. Unlike 14 and 15, in which the OH 277 
group of the phenethyl moiety establishes an H-bond with the backbone of Trp110, 21 adopts 278 
a different conformation that favors the interaction between Ser315 and OH at C3 from A-ring. 279 
Additionally, a better hydrophobic interaction with Trp110 can be observed for this compound 280 
(Figure S3). These results may explain, at least in part, the significant inhibitory activity found 281 
for compound 21. 282 
 283 
3. Conclusions 284 
The synthesis of a series of N-benzyl-2-phenylethanamine derivatives was optimized and 285 
performed by a simple methodology involving a reductive amination affording the products with 286 
moderate to excellent yields. Most of these compounds exerted significant in vitro inhibition of 287 
AChE and BChE. In particular, brominated norbelladine analogues showed the highest 288 
inhibition values, whereas the presence of iodine showed a high selectivity towards BChE with 289 
a strong IC
50
 value comparable to galantamine. Moreover, the lack of hydroxyl group on the B-290 
ring had an influence on the inhibition of BChE showing a high inhibition with similar values for 291 
both enzymes. All these observations can be explained by molecular modeling studies 292 
considering the size and structural features of the active sites of both enzymes. Due to the 293 
presence of different halogens on one of the aromatic rings, these compounds can adopt 294 
different conformations that allow some of them to accommodate very well in the active site by 295 
establishing the necessary interactions to stabilize the molecular complexes. These results 296 
can be very useful for the design and development of new inhibitors possessing similar 297 
structural characteristics. 298 
 299 
 300 


































































































































4. Experimental Section 301 
4.1. General experimental procedures 302 
4.1.1. Chemicals 303 
3-Hydroxy-4-methoxybenzaldehyde (1), 4-fluorobenzaldehyde (6), 4-chlorobenzaldehyde (7), 304 
4-bromobenzaldehyde (8), 4-hydroxybenzaldehyde (9), tyramine (10), phenylethylamine (11) 305 
were purchased from Sigma–Aldrich, Argentina. Aldehydes 2-5 were prepared by 306 
halogenation reactions. Compounds 12-21 were obtained by reductive amination as described 307 
in Section 4.2.3. Their NMR spectra and GC-FID or GC-MS chromatograms are shown in the 308 
Supplementary Material. 309 
4.1.2. Analytical methods 310 
Thin-layer chromatography (TLC) was performed on silica gel 60 F254 plates (Merck) using n-311 
hexane:ethyl acetate mixtures of different polarity for halogenated aldehydes and 312 
diclorometane:methanol:NH4OH (80:15:5) for norbelladine analogues and visualized by UV 313 
irradiation at 254 nm and further sprayed with acidic anisaldehyde solution. The GC-FID and 314 
GC-MS analyses were performed using a Perkin Elmer Clarus 500 and a Thermo Trace 1300 315 
gas chromatograph coupled to an ITQ900 ion trap mass spectrometer (GC/MS-ITQ Thermo 316 
Scientific), respectively. 1H and 13C NMR spectra were recorded using a Bruker AC-200 317 
spectrometer in CDCl3 or D2O at 200 and 50 MHz or Bruker Avance 400 MHz spectrometer at 318 
400 and 100 MHz, respectively. Melting points were determined with Leitz Wetzlar 553174 319 
(1.25 X) apparatus (Germany). 320 
4.2. Synthesis 321 
4.2.1. Synthesis of halogenated aldehydes 322 
2-bromo-3-hydroxy-4-methoxybenzaldehyde (2) 323 
NBS (1.75 g, 9.86 mmol) was dissolved in 60 mL of glacial acetic acid. A solution of 3-324 
hydroxy-4-methoxybenzaldehyde (1) (1.5 g, 9.86 mmol) in 30 mL of glacial acetic acid, was 325 
added dropwise. The reaction mixture was stirred at room temperature for 4 h. After that the 326 
precipitated solid was filtered and washed with glacial acetic acid and then with water.  Finally, 327 
the product was dried under vacuum to obtain 2 as a white solid (1.51 g, 66 % yield). Mp: 200 328 
°C (Mp. Lit. 210 °C 38). 1H NMR (200 MHz, CDCl3) δ 4.01 (s, 3H, CH3), 6.08 (s, 1H, OH), 6.93 329 


































































































































(d, J = 8.6 Hz, 1H, Ar), 7.58 (d, J = 8.6 Hz, 1H, Ar), 10.26 (s, 1H, CHO). 13C NMR (50 MHz, 330 
CDCl3) δ 56.7, 109.4, 113.0, 122.9, 127.3, 143.3, 151.8, 191.1. 331 
6-bromo-3-hydroxy-4-methoxybenzaldehyde (3) 332 
To obtain 3 we followed the methodology described by Hazlet and Brotherton 39 with 333 
modifications. To a solution of 1 (1 g, 6.6 mmol) in 25 mL of chloroform, a solution of bromine 334 
(1.5 g, 9.5 mmol) in 10 mL of chloroform was added dropwise. The mixture was heated at 60 335 
°C by reflux under argon atmosphere for 1 hour. The reaction was stopped in absence of 336 
starting material and evaporated to dryness. The solid was resuspended in ethyl acetate and 337 
washed with sodium thiosulfate solution (10 %) to eliminate the bromine excess. The organic 338 
phase was washed with H2O and the aqueous phase with chloroform. Organic phases were 339 
dried and evaporated and the crude product was purified by chromatography on silica gel (70–340 
230 mesh, Sigma-Aldrich) with dichloromethane to afford a pale brown solid (1.1 g, 73 % 341 
yield). Mp: 118-120 °C (Mp. Lit. 112-114°C. 40). 1H NMR (200 MHz, CDCl3) δ 3.99 (s, 3H, 342 
CH3), 5.63 (s, 1H, OH), 7.06 (s, 1H, Ar), 7.48 (s, 1 H, Ar), 10.18 (s, H, CHO).
 13C NMR (100 343 
MHz, CDCl3) δ 56.6, 114.6, 115.1, 118.7, 127.4, 145.4, 151.9, 190.8. 344 
2-chloro-3-hydroxy-4-methoxybenzaldehyde (4) 345 
To a solution of 3-hydroxy-4-methoxybenzaldehyde (1) (1.5 g, 9.86 mmol) in 30 mL of glacial 346 
acetic acid, was added dropwise a solution of NCS (1.97 g, 14.8 mmol) in 60 mL of glacial 347 
acetic acid. The reaction was carried out for 24 h. The precipitated solid formed was filtered 348 
and washed with glacial acetic acid and water to yield 4. The resulting product was a white 349 
solid (582 mg, 48 % yield). Mp: 187-189 °C. 1H NMR (200 MHz, CDCl3) δ 4.01 (s, 3H, CH3), 350 
5.97 (s, 1H, OH), 6.90 (d, 1H, J = 8.6 Hz, Ar), 7.57 (d, 1H, J = 8.6 Hz, Ar), 10.35 (s, 1H, CHO). 351 
13C NMR (50 MHz, CDCl3) δ 56.7, 108.9, 122.2, 123.2, 126.5, 142.3, 152, 189.1. 352 
3-hydroxy-2-iodo-4-methoxybenzaldehyde (5)  353 
The iodination of 3-hydroxy-4-methoxybenzaldehyde was obtained according to literature 41 354 
with modifications. 3-Hydroxy-4-methoxybenzaldehyde (1.5 g, 9.86 mmol) and NaI (1.73 g, 355 
11.53 mmol) was dissolved in EtOH (30 mL). NaClO (16.4 mL, 9.86 mmol) was added 356 
dropwise to the solution. The precipitate formed was filtered and washed with cold water. The 357 
ocher solid was obtained in 46 % yield. Mp: 170-172 °C. 1H NMR (200 MHz, CDCl3-DMSO-d6) 358 
δ 4.00 (s, 3H, CH3), 6.93 (d, 1H, J = 8.5 Hz, Ar), 7.56 (d, 1H, J = 8.5 Hz, Ar), 10.04 (s, 1H, 359 
CHO). 13C NMR (50 MHz, CDCl3) δ 56.7, 88.2, 110.1, 124.0, 128.8, 145.8, 150.8, 194.9.  360 



































































































































4.2.3. General procedure for the synthesis of N-benzyl-2-phenylethanamines (12-21)  362 
To obtain the norbelladine analogues, we followed the procedure described by Tachy et al. 26 363 
with modifications. Aldehydes 1-9 (2.16 mmol) and amines 10-11 (2.16 mmol) were dissolved 364 
in MeOH (12 mL) and anhydride Na2SO4 and triethylamine (TEA) (400 µL) or KOH (100 mg) 365 
were added. The reaction was stirred overnight under inert atmosphere. After that, the imine 366 
formed was reduced with NaBH4 (2.16 mmol) on ice bath until no starting material was 367 
observed by TLC. The solvent was evaporated and the solid was resuspended in water. The 368 
pH of the aqueous phase was adjusted to the corresponding theoretical isoelectric point of the 369 
products. The precipitated product was filtered and dried under vacuum. The solid was 370 
dissolved in hot ethanol and after cooling, the suspension was filtered. The resulting solid was 371 
dried to yield the desired product. To obtain the corresponding hydrochloride, each compound 372 
was dissolved in absolute EtOH and then HCl was added in equimolar relation with the 373 
product. The reaction was stirred for 3 h and after that, the solvent was evaporated and the 374 
residue washed with acetone. 375 
N-(p-hydroxyphenylethyl)-N-(3-hydroxy-4-methoxy)benzylamine (12) beige solid. 51 % yield. 376 
Mp: 206-208 °C (Mp. Lit. 208° 26). 1H NMR (200 MHz, D2O) as hydrochloride: δ 2.92 (m, 2H, 377 
CH2), 3.25 (m, 2H, CH2), 3.88 (s, 3H, OCH3), 4.11 (s, 2H, CH2), 6.85-7.18 (m, 7H, Ar). 
13C 378 
NMR (50 MHz) 30.5, 47.5, 50.2, 55.7, 112.4, 115.6, 116.5, 122.5, 123.2, 128.0, 130.0, 144.9, 379 
148.2, 154.4. 380 
N-(p-hydroxyphenylethyl)-N-(2-chloro-3-hydroxy-4-methoxy)benzylamine (13) Light brown 381 
solid. 66 % yield. Mp: 172 °C. 1H NMR (200 MHz, CDCl3) δ 2.72-2.82 (m, 4H, CH2-CH2), 3.82 382 
(s, 2H, CH2), 3.87 (s, 3H, OCH3), 6.69-6.82 (m, 4H, Ar), 7.00 (d, J = 8.4 Hz, 2H, Ar).
 13C NMR 383 
(100 MHz, D2O) as hydrochloride: δ 30.5, 47.9, 48.2, 56.2, 110.3, 115.7, 120.7, 121.0, 123.4, 384 
128.0, 130.1, 142.0, 149.5, 154.6. 385 
N-(p-hydroxyphenylethyl)-N-(2-bromo-3-hydroxy-4-methoxy)benzylamine (14) light brown 386 
solid. 77 % yield. Mp: 185-187 °C. 1H NMR (200 MHz, CDCl3) δ 2.75-2.85 (m, 4H, CH2-CH2), 387 
3.83 (s, 2H, CH2), 3.87 (s, 3H, OCH3), 6.67-6.86 (m, 4H, Ar), 7.02 (d, J = 8.3, 2H, Ar).
 13C NMR 388 
(100 MHz, D2O) as hydrochloride: 30.4, 47.8, 50.9, 56.1, 110.7, 111.4, 115.6, 122.4, 123.5, 389 
127.8, 130.0, 143.0, 149.0, 154.4. 390 


































































































































N-(p-hydroxyphenylethyl)-N-(2-iodo-3-hydroxy-4-methoxy)benzylamine (15) Ocher solid 49 % 391 
yield. Mp: 202-205 °C (as hydrochloride). 1H NMR (400 MHz, D2O) as hydrochloride δ 2.93-392 
3.36 (m, 4H, CH2-CH2), 3.87 (s, 2H, CH2), 4.32 (s, 3H, OCH3), 6.84 (d, J = 8.2 Hz, 2H, Ar), 393 
7.02 (s, 2H, Ar), 7.15 (d, J = 8.2 Hz, 2H, Ar). 13C NMR (100 MHz, D2O) δ 30.6, 48.0, 54.9, 394 
56.2, 89.4, 111.7, 115.8, 123.5, 126.0, 127.9, 130.1, 145.8, 147.8, 154.6. 395 
N-(p-hydroxyphenylethyl)-N-(6-bromo-3-hydroxy-4-methoxy)benzylamine (16) Pale yellow 396 
solid. 56 % yield. Mp: 122-125 °C. 1H NMR (200 MHz, CDCl3) δ 2.75- 2.84 (m, 4H, CH2-CH2), 397 
3.75 (s, 2H, CH2), 3.85 (s, 3H, OCH3), 6.73 (d, J = 8.4 Hz, 2H, Ar), 6.88 (s, 1H, Ar), 6.96 (s, 398 
1H, Ar), 7.05 (d, J = 8.4 Hz, 2H, Ar). 13C NMR (100 MHz, CDCl3) δ 35.4, 50.3, 53.1, 56.2, 399 
112.6, 115.0, 115.3, 116.2, 129.8, 132.1, 144.9, 146.1, 153.8.  400 
N-(p-hydroxyphenylethyl)-N-(p-fluor)benzylamine (17) yellow solid. 51 % yield. Mp: 163-165 401 
°C. 1H NMR (400 MHz, D2O) as hydrochloride δ 2.91-3.28 (m, 4H, CH2-CH2), 4.20 (s, 2H, 402 
CH2), 6.87 (d, 2H, Ar), 7.15-7.21 (m, 4H, Ar), 7.42-7.46 (m, 2H, Ar). 
13C NMR (200 MHz, D2O) 403 
δ 30.7, 47.9, 50.2, 115.8, 116.0, 116.2, 126.6, 128.2, 130.2, 132.0, 132.1, 154.6, 162.0, 164.4. 404 
N-(p-hydroxyphenylethyl)-N-(p-chloro)benzylamine (18) pale yellow solid. 55 % yield. Mp: 123-405 
126 °C. 1H NMR (400 MHz, D2O) as hydrochloride δ 2.91- 3.28 (m, 4H, CH2-CH2) 4.20 (s, 2H, 406 
CH2), 6.87 (d, J = 8.4 Hz, 2H, Ar), 7.16 (d, J = 8.3, 2H, Ar), 7.39 (d, J = 8.4, 2H, Ar), 7.46 (d, J 407 
= 8.4, 2H, Ar). 13C NMR (100 MHz, CDCl3) δ 30.6, 47.9, 50.1, 115.7, 128.1, 129.1, 129.2, 408 
130.1, 131.3, 135.0, 154.5. 409 
N-(p-hydroxyphenylethyl)-N-(p-bromo)benzylamine (19) white solid. 84 % yield. Mp: 140-143 410 
°C. 1H NMR (200 MHz, CDCl3) δ 2.75-2.84 (m, 4H, CH2-CH2), 3.75 (s, 2H, CH2), 6.73 (d, J = 411 
8.3 Hz, 2H, Ar), 7.04 (d, J = 8.3 Hz, 2H, Ar), 7.15 (d, J = 8.2 Hz, 2H, Ar), 7.42 (d, J = 8.2 Hz, 412 
2H, Ar). 13C NMR (100 MHz, CDCl3) δ 35.2, 50.5, 53.2, 115.6, 121.0, 129.9, 130.1, 131.4, 413 
131.7, 138.8, 154.6. 414 
N-(p-hydroxyphenylethyl)-N-(p-hydroxy)benzylamine (20) white solid. 92 % yield. Mp: 220-222 415 
°C (as hydrochloride). 1H NMR (400 MHz, D2O) as hydrochloride δ 2.87-3.23 (m, 4H, CH2-416 
CH2), 4.11 (s, 2H, CH2), 6.84 (d, J = 8.5 Hz, 2H, Ar), 6.90 (d, J = 8.5, 2H, Ar), 7.13 (d, J = 8.5 417 
Hz, 2H, Ar), 7.28 (d, J = 8.5 Hz, 2H, Ar). 13C NMR (100 MHz, D2O) δ 30.6, 47.6, 50.3, 115.8, 418 
122.3, 128.2, 130.1, 131.6, 154.5, 156.5. 419 
N-(phenylethyl)-N-(2-bromo-3-hydroxy-4-methoxy)benzylamine (21) pale yellow solid. 55 % 420 
yield. Mp: 102-105 °C. 1H NMR (400 MHz, CDCl3) 2.85-2.96 (m, 4H, CH2CH2), 3.89 (s, 3H, 421 


































































































































OCH3), 3.91 (s, 2H, CH2), 6.76 (d, J = 8.3 Hz, 1H, Ar), 6.88 (d, J = 8.3 Hz, 1H, Ar), 7.18-7.30 422 
(m, 5H, Ar). 13C NMR (100 MHz, CDCl3) δ 35.2, 49.2, 52.4, 56.3, 109.4, 110.3, 121.5, 126.4, 423 
128.6, 128.7, 138.9, 143.3, 146.6. 424 
 425 
4.3. Microplate assay for AChE and BChE inhibitory activities 426 
The enzymes AChE from Electrophorus electricus (EeAChE) and BChE from equine serum 427 
(EqBChE) (Sigma-Aldrich) were used. For the AChE and BChE activity assay, 428 
acetylthiocholine iodide and butyrylthiocholine iodide were used as substrates, respectively. 429 
Briefly, 50 µL of AChE or BChE in phosphate-buffered saline (PBS) (8 mM K2HPO4, 2.3 mM 430 
NaH2PO4, 0.15 M NaCl, pH 7.6) and 50 µL of the sample dissolved in the same buffer, were 431 
added to the wells of a microplate. When necessary, the compounds were dissolved in 432 
dimethyl sulfoxide (DMSO) or methanol at a final concentration of 0.02 % and 0.5 %, 433 
respectively The plates were incubated for 30 min at room temperature before the addition of 434 
100 µL of the substrate solution (0.1 M Na2HPO4, 0.5 M DTNB, 0.6 mM ATCI in Millipore 435 
water, pH 7.5). The absorbance was read in a Thermo Scientific Multiskan FC microplate 436 
photometer at 405 nm after 5 min. Enzyme inhibitory activity was calculated as a percentage 437 
compared to an assay using buffer without any inhibitor. The results obtained were analyzed 438 
with the software package Prism (Graph Pad Inc., San Diego, CA, USA). The values were 439 
expressed as half-maximal inhibitory concentration IC50 (µM), and were calculated as means ± 440 
SD of 3 individual determinations. Galantamine (Sigma-Aldrich) was used as a positive 441 
control. 442 
 443 
4.4. Molecular Modeling Studies 444 
3D models of Torpedo californica AChE (TcAChE) (1DX6) 42 and Equus caballus BChE 445 
(EqBChE) (UniProtAC Q9N1N9) available at Protein Data Bank (http://www.rcsb.org) were 446 
used for carring out the molecular modeling studies. Water molecules and ligands were 447 
removed from the structures before performing the docking calculations. Receptors and N-448 
benzyl-2-phenylethanamine derivatives structures were converted from pdb to pdbqt format 449 
using AutoDockTools 1.5.4 43. Gasteiger charges were added for all the compounds and non-450 
polar hydrogen atoms were merged. AutoDockTools 43 was also used to perform further 451 
graphic manipulations and visualizations required. For docking procedures, Autodock version 452 


































































































































4.0 44 was used. The receptor structure was set as rigid and grid dimension were 60 60 60 for 453 
the X, Y and Z axes, respectively, in the catalytic site of TcAChE and EqBChE with a spacing 454 
resolution of 0.375 Å in both cases. All torsions of the ligand were allowed to rotate during 455 
docking. The number of collected poses was 200. Other parameters were set to default 456 
values. The resulting docked conformations were clustered into families based on the rmsd 457 
between the coordinates of the ligands and were ranked regarding to the binding free energy 458 
of complexes. The structure with lower binding free energy from the cluster with the largest 459 
number of members was chosen as the optimum docking conformation and was used in 460 
subsequent simulations. 461 
MD simulations for all complexes selected from docking procedures were performed using the 462 
Amber16 software package 45. Antechamber software 46 was used to generate their 463 
parameters with FF99SB 47 and GAFF 48 force fields. The complex geometries from docking 464 
were soaked in truncated octahedral periodic boxes of explicit water using the TIP3P model 49 465 
with a margin of 10.0 Å in each direction from the solute. Na+ or Cl- ions were placed by Leap 466 
to neutralize the negative and positive charges of AChE and BChE complexes, respectively. 467 
The energy of each system was then minimized with sander module using a steepest-descent 468 
algorithm for 1000 steps. There upon the complexes were equilibrated during 500 ps at 469 
constant volume. The SHAKE algorithm 50 was applied allowing for an integration time step of 470 
2 fs. The systems were heated from 0 to 300 K using Langevin thermostat 51 in order to control 471 
temperature, collision frequency = 1.0 ps-1. Next, three MD simulations were conducted for 472 
each complex at 298 K target temperature. All production was performed under NVT 473 
conditions. The particle mesh Ewald (PME) method 52 was applied using a grid spacing of 1.2 474 
Å, a spline interpolation order of 4, and a real space direct sum cutoff of 8.0 Å. Simulation time 475 
was set to 20 ns, the time step was set to 2.0 fs and coordinates were saved for analysis every 476 
10 ps. Post MD analysis was performed with the program PTRAJ 53. A per-residue interaction 477 
energy decomposition analysis using mm_pbsa program was carried out in order to determine 478 
the residues of AChE and BChE that interact with each ligand. For mm_pbsa methodology 54, 479 
snapshots from the corresponding last 1000 ps of MD trajectories were considered. The 480 
explicit water molecules and counter ions were removed from the snapshots. 481 
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